NCT06780670 - Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy | Biotech Hunter

Enrollment

432

Participants

Timeline

Start Date

February 27, 2025

Primary Completion Date

March 20, 2028

Study Completion Date

April 11, 2033

Conditions

Prostate Cancer

Interventions

DRUG

Investigators choice of SoC

The control treatment in Phase III is investigator's choice of SoC

DRUG

AAA817

The investigational treatment is AAA817

DRUG

AAA817

The investigational treatment is AAA817

DRUG

AAA817

Investigational treatment is the Dose B of AAA817

Trial Locations (17)

2010

RECRUITING

Novartis Investigative Site, Darlinghurst

4029

RECRUITING

Novartis Investigative Site, Herston

10002

RECRUITING

Novartis Investigative Site, Taipei

63110

RECRUITING

WA Uni School Of Med, St Louis

100036

RECRUITING

Novartis Investigative Site, Beijing

119228

RECRUITING

Novartis Investigative Site, Singapore

168583

RECRUITING

Novartis Investigative Site, Singapore

300308

RECRUITING

Novartis Investigative Site, Tianjin

610041

RECRUITING

Novartis Investigative Site, Chengdu

6423906

RECRUITING

Novartis Investigative Site, Tel Aviv

02115

RECRUITING

Dana Farber Cancer Institute, Boston

277 8577

RECRUITING

Novartis Investigative Site, Kashiwa

060 8648

RECRUITING

Novartis Investigative Site, Sapporo

650-0047

RECRUITING

Novartis Investigative Site, Kobe

920 8641

RECRUITING

Novartis Investigative Site, Kanazawa

236-0004

RECRUITING

Novartis Investigative Site, Yokohama

606 8507

RECRUITING

Novartis Investigative Site, Kyoto